Top Story Today
Roche Builds Pharma's Largest Supercomputer, and It's Already Discovering Drugs
Roche deployed 2,176 NVIDIA Blackwell GPUs across its U.S. and European facilities, bringing its total to over 3,500 chips and making it the largest GPU footprint in pharma history. For context, Eli Lilly (the runner-up) has about 1,016. The hardware powers Genentech's "Lab-in-the-Loop" platform, where AI models analyze wet-lab results, predict what experiments to run next, and feed those findings back into the cycle. Early results show dramatically improved molecule selection. This isn't a pilot project; it's integrated across Genentech's small-molecule programs.
Why it matters: When a pharma giant decides that computing power is as strategically important as lab equipment, it signals a structural shift in how the industry discovers drugs. The pharma AI arms race is officially here, and the companies without infrastructure may find themselves playing catch-up for years.
Read more →Deals and Dealmaking
Two Pharma Giants Bet on Protein Destruction in the Same Week
Gilead paid Kymera $40 million upfront and later a $45 million option-exercise payment (with up to $750 million in total deal value) for global rights to KT-200, a preclinical drug that doesn't block cancer proteins but destroys them entirely using the cell's own recycling system. The same week, Roche committed over $1 billion in milestones to C4 Therapeutics for degrader-antibody conjugates. Two big pharma bets on the same modality within 24 hours is a signal worth watching.
Read more →Roche's 'Leap of Faith' on Cancer-Killing Guided Missiles
Roche paid C4 Therapeutics $20 million upfront, with over $1 billion in milestone potential, to co-develop degrader-antibody conjugates for cancer. The tech attaches protein-destroying payloads to antibodies that home in on tumor cells. Roche's own executive called it a "leap of faith," but the two companies have been collaborating for a full decade.
Read more →The Small MIT Spinout That Just Landed $2.1B From Novo Nordisk
Vivtex built a miniature gut on a chip, then convinced Novo Nordisk to bet up to $2.1 billion on it. The Boston startup's robotics-driven platform tests thousands of oral drug formulations daily against a replica of the human digestive tract. The goal: turn injectable obesity drugs into pills. Vivtex has around 20 employees and says the deal puts it on a path to early profitability.
Read more →Akari Walks Into a Geopolitical Minefield With WuXi ADC Partnership
Akari Therapeutics partnered with WuXi XDC to manufacture its cancer ADC, just months after the BIOSECURE Act became law. WuXi isn't officially designated a "company of concern" yet, but the OMB list is still pending. Akari's preclinical data for AKTX-101 looks promising, and WuXi holds 22% of the global bioconjugate manufacturing market. The calculated gamble: speed now, regulatory risk later.
Read more →GLP-1 Wars
Novo Fires the Shot Heard Round the Pharmacy Counter
Novo Nordisk launched a higher-dose Wegovy (7.2 mg) at $399 per month, roughly 40% below comparable Zepbound pricing. Subscription plans drop it to $249 monthly. Clinical trials showed 20.7% average weight loss over 72 weeks. Wall Street isn't cheering though: Novo's stock is down over 50% from its highs, as analysts worry the company is trading margin for volume in a fight Eli Lilly is still winning.
Read more →Funding and Financings
An $80M Bet That You Can Reverse Aging Inside the Human Eye
Life Biosciences raised $80 million to advance the first epigenetic reprogramming therapy ever tested in humans. The gene therapy (ER-100) uses three Yamanaka factors to partially reset aging retinal cells, controlled by a 56-day course of oral doxycycline that acts as an on/off switch. The Phase 1 trial targets glaucoma and optic nerve damage, with preclinical primate data showing restored visual function.
Read more →Uncle Sam Is Paying Japan to Make America's Antibiotics
BARDA awarded Shionogi $119 million (expandable to $482 million) to build a U.S. factory for Fetroja, an antibiotic that tricks resistant bacteria into swallowing their own poison. The backdrop: America can't domestically produce basic antibiotics like penicillin, with over 60% of active ingredients sourced from China. The contract also covers development against biodefense threats including plague.
Read more →Avalyn Pharma Files for $100M IPO to Fund Inhaled Lung Disease Drugs
Avalyn filed to raise $100 million on Nasdaq, pitching inhaled versions of existing pulmonary fibrosis drugs that could slash the brutal side effects of oral treatments. Early data showed patients on its lead candidate lost only 69 mL of lung capacity per year, a striking reduction compared to historical benchmarks. The company is still in Phase 2, testing whether the IPO window is truly open for mid-stage stories.
Read more →